^
Association details:
| Biomarker: | TP53 exon 8 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Published date:
09/01/2021
Excerpt:
Post hoc analysis revealed PFS benefits tended to favor the A + G group in patients with TP53 exon 8 mutation....for patients with TP53 mutation, HR for PFS favored the A + G group than the P + G group (HR = 0.56, 95% CI: 0.31–1.01...Patients with TP53 exon 8 mutation had a better tendency for PFS in the A + G group (HR = 0.24, 95% CI: 0.06–0.91...
DOI:
https://doi.org/10.1016/j.jtho.2021.05.006
Trial ID:
Source:
Title:
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Published date:
09/19/2020
Excerpt:
...NGS results of baseline samples showed a marginally significant improved PFS in TP53-mutant disease. Pts with TP53 exon 8 mutation significantly benefited from dual blockade (HR = 0.24, 0.06-0.91)….Apatinib plus gefitinib as first-line therapy demonstrated superior PFS. TP53 exon 8 mutation status could serve as an efficacy predictor.
Trial ID:
